3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
3
Unknown
1
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
5
Relapsed Pediatric Solid Tumor
2
Ovarian Neoplasms
2
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Breast Neoplasms
1
Interventions
aldesleukin
9
Sunitinib
5
Interferon-alpha
4
Chemotherapy, Adjuvant
4
pembrolizumab
3
Vincristine
3
Neoadjuvant Therapy
3
Dactinomycin
3
Cyclophosphamide
3
Bevacizumab
3
sargramostim
2
fludarabine phosphate
2
Robotic Surgical Procedures
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Laparoscopy
2
Gene Expression Profiling
2
Fluorouracil
2
Etoposide
2
Electroporation
2
Doxorubicin
2
Carboplatin
2
Blood Specimen Collection
2
Amplified Fragment Length Polymorphism Analysis
2
tremelimumab
1
toripalimab
1
temsirolimus
1
spartalizumab
1
pazopanib
1
orantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Kidney Neoplasms
×
pazopanib
×
Clear all
NCT03571438
2020-01-18
COMBOREIN
University Hospital, Grenoble
Phase NA
Unknown
100 enrolled